Enterprise Therapeutics, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, has announced that it has appointed Dr John Ford as CEO.

John is a successful biotechnology entrepreneur who has co-founded Xention, Ario Pharma and Metrion Biosciences. Recently, he was a member of the Executive Team at Dezima that developed TA-8995 for dyslipidaemia and later sold the company to Amgen in 2015 for up to $1.55 billion. He has over 18 years' ion channel research, drug discovery and development experience.